Funded Tech Companies
Ratio Therapeutics
Ratio Therapeutics, based in Boston, received equity investments from Duquesne Capital Management, The Pags Group and Bristol Myers Squibb.
Company Overview
Company Name
Ratio Therapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
77 Sleeper St
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics' Trillium� targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
1/17/2024
Financing History
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jack Hoppin
Chief Financial Officer
Reed Malleck
Chief Operating Officer
Shawn Hillier
Chief Scientific Officer
John Babich
Chief Technical Officer
Matthias Friebe
Company Investors
- Duquesne Capital Management
- The Pags Group
- Bristol Myers Squibb
- Cornell University
- Schusterman Foundation
Browse more funded tech companies:
Share this article
About Our VC Funding Database
This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs